Phase I/II study of combination therapy with S-1 and CPT-11 for metastatic colorectal cancer

  • Authors:
    • Yuji Nakafusa
    • Masayuki Tanaka
    • Takao Ohtsuka
    • Atsushi Miyoshi
    • Naohiko Kohya
    • Yoshihiko Kitajima
    • Seiji Sato
    • Sakiko Mochinaga
    • Sawako Dohi
    • Kohji Miyazaki
  • View Affiliations

  • Published online on: November 1, 2008     https://doi.org/10.3892/mmr_00000051
  • Pages: 925-930
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

We conducted a Phase I/II study of combination therapy using CPT-11 and S-1 as a first-line treatment for metastatic colorectal cancer. The 28-day treatment cycle consisted of S-1 administered orally from day 1 to 21 and CPT-11 administered intravenously on days 1 and 15. In the Phase I portion, the dose of S-1 was fixed at 80 mg/m2/day, while CPT-11 was administered at a starting dose of 60 mg/m2 then stepped up in 20 mg/m2 increments. The maximum-tolerated dose was achieved at 80 mg/m2 of CPT-11, and the recommended dose was determined to be 60 mg/m2 of CPT-11. In the Phase II portion, this therapy exhibited a response rate of 58%, a median progression-free survival of 8.4 months, and a median overall survival of 18.7 months. Toxicity was generally mild and manageable. No patient showed grade 4 toxicity, and grade 3 toxicity was observed in only 18% of patients. The most frequently observed grade 3 toxicity was diarrhea, at a rate of 6%. The mean relative dose intensity of CPT-11 and S-1 was as high as 98 and 97%, respectively. In conclusion, combination therapy with CPT-11 and S-1 according to our treatment schedule is effective, safe and highly feasible for metastatic colorectal cancer patients. These data suggest that assessing this combination therapy in a Phase III study would be worthwhile.

Related Articles

Journal Cover

November 2008
Volume 1 Issue 6

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Nakafusa, Y., Tanaka, M., Ohtsuka, T., Miyoshi, A., Kohya, N., Kitajima, Y. ... Miyazaki, K. (2008). Phase I/II study of combination therapy with S-1 and CPT-11 for metastatic colorectal cancer. Molecular Medicine Reports, 1, 925-930. https://doi.org/10.3892/mmr_00000051
MLA
Nakafusa, Y., Tanaka, M., Ohtsuka, T., Miyoshi, A., Kohya, N., Kitajima, Y., Sato, S., Mochinaga, S., Dohi, S., Miyazaki, K."Phase I/II study of combination therapy with S-1 and CPT-11 for metastatic colorectal cancer". Molecular Medicine Reports 1.6 (2008): 925-930.
Chicago
Nakafusa, Y., Tanaka, M., Ohtsuka, T., Miyoshi, A., Kohya, N., Kitajima, Y., Sato, S., Mochinaga, S., Dohi, S., Miyazaki, K."Phase I/II study of combination therapy with S-1 and CPT-11 for metastatic colorectal cancer". Molecular Medicine Reports 1, no. 6 (2008): 925-930. https://doi.org/10.3892/mmr_00000051